Biogen Inc. (NASDAQ:BIIB – Get Rating) – Equities researchers at Wedbush decreased their Q2 2022 earnings per share (EPS) estimates for Biogen in a research note issued to investors on Tuesday, May 3rd. Wedbush analyst L. Chico now forecasts that the biotechnology company will earn $3.86 per share for the quarter, down from their previous forecast of $3.97. Wedbush has a “Neutral” rating on the stock. Wedbush also issued estimates for Biogen’s Q3 2022 earnings at $3.41 EPS, Q4 2022 earnings at $4.01 EPS, FY2022 earnings at $14.90 EPS, Q2 2023 earnings at $4.02 EPS, Q3 2023 earnings at $3.94 EPS, Q4 2023 earnings at $3.97 EPS and FY2023 earnings at $15.88 EPS.
Biogen (NASDAQ:BIIB – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported $3.62 EPS for the quarter, missing the consensus estimate of $4.38 by ($0.76). Biogen had a return on equity of 23.46% and a net margin of 13.40%. The business had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the firm earned $5.34 EPS. The firm’s quarterly revenue was down 6.1% compared to the same quarter last year.
Shares of NASDAQ BIIB opened at $201.18 on Friday. The stock has a market cap of $29.60 billion, a P/E ratio of 20.59, a P/E/G ratio of 1.28 and a beta of 0.42. The firm has a 50 day moving average price of $209.04 and a 200 day moving average price of $228.96. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.51 and a current ratio of 2.01. Biogen has a 52-week low of $192.67 and a 52-week high of $468.55.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Avondale Wealth Management bought a new stake in Biogen during the fourth quarter worth $26,000. Equitec Proprietary Markets LLC bought a new stake in Biogen during the fourth quarter worth $27,000. EverSource Wealth Advisors LLC bought a new stake in Biogen during the fourth quarter worth $27,000. Amplius Wealth Advisors LLC acquired a new position in shares of Biogen in the fourth quarter valued at $28,000. Finally, Evolution Wealth Advisors LLC increased its holdings in shares of Biogen by 96.7% in the third quarter. Evolution Wealth Advisors LLC now owns 120 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. 83.92% of the stock is currently owned by hedge funds and other institutional investors.
About Biogen (Get Rating)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
- Get a free copy of the StockNews.com research report on Biogen (BIIB)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.